financetom
Business
financetom
/
Business
/
Databricks to buy data management firm Tabular for over $1 bln
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Databricks to buy data management firm Tabular for over $1 bln
Jun 4, 2024 12:01 PM

June 4 (Reuters) - Databricks said on Tuesday it would

buy data-management startup Tabular for more than $1 billion, as

the privately held analytics platform looks to attract customers

by helping them develop custom artificial intelligence (AI)

applications.

The announcement comes at a time when companies are doubling

down efforts to build an ecosystem for clients to use

open-source AI models, in a bid to gain market share from rivals

such as Snowflake and Cloudera, among others, in a

highly competitive market.

Tabular, founded by Ryan Blue, Daniel Weeks and Jason Reid

in 2021, provides an independent and universal storage platform

to its customers.

San Francisco, California-based Databricks said Tabular's

team of about 40 members will join it after the transaction is

completed in its second quarter ending July 31.

The frenzy around AI has sparked the need for robust

infrastructure to store and manage corporate data, as companies

create their own large language models after the launch of

OpenAI's viral chatbot ChatGPT.

Databricks' primary product is a technology for holding huge

troves of corporate data in a way that makes it easy to access

and analyze. But doing so still typically requires a data

scientist to write computer code that finds and manipulates the

data.

The company had agreed to acquire AI startup MosaicML in a

deal valued at $1.3 billion in June last year.

Databricks counts AT&T ( T ), Warner Bros Discovery ( WBD )

and Rivian Automotive ( RIVN ), among others, as its customers.

Last year, Databricks had secured more than $500 million in

a funding round that valued it at $43 billion, marking one of

the biggest funding events for private tech companies in 2023

amid AI-fueled optimism.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Revolution Medicines Insider Sold Shares Worth $1,280,412, According to a Recent SEC Filing
Revolution Medicines Insider Sold Shares Worth $1,280,412, According to a Recent SEC Filing
Mar 20, 2026
04:29 AM EDT, 03/20/2026 (MT Newswires) -- Mark A Goldsmith, Director, President and Chief Executive Officer, on March 17, 2026, sold 12,871 shares in Revolution Medicines ( RVMD ) for $1,280,412. Following the Form 4 filing with the SEC, Goldsmith has control over a total of 999,606 common shares of the company, with 276,698 shares held directly and 722,908 controlled...
Guardian Metal Resources Prices Upsized $60 Million IPO
Guardian Metal Resources Prices Upsized $60 Million IPO
Mar 20, 2026
03:42 AM EDT, 03/20/2026 (MT Newswires) -- Guardian Metal Resources ( GMTL ) said late Thursday it priced its upsized $60 million initial public offering in the US. The exploration stage company is issuing 4.4 million American depositary shares, representing 22.2 million ordinary shares, at a price of $13.50 per ADS. Guardian Metal has granted underwriters a 45-day option to...
Novartis Agrees to Buy Synnovation Therapeutics Unit For Up to $3 Billion
Novartis Agrees to Buy Synnovation Therapeutics Unit For Up to $3 Billion
Mar 20, 2026
03:42 AM EDT, 03/20/2026 (MT Newswires) -- Novartis ( NVS ) said Friday it agreed to buy Pikavation Therapeutics, a Synnovation Therapeutics unit, for $2 billion upfront and up to $1 billion in milestone payments. The acquisition of Pikavation Therapeutics includes a portfolio of targeted enzyme inhibitors, featuring a lead oral drug currently undergoing early-to-mid-stage clinical trials for advanced solid...
Revolution Medicines Insider Sold Shares Worth $455,919, According to a Recent SEC Filing
Revolution Medicines Insider Sold Shares Worth $455,919, According to a Recent SEC Filing
Mar 20, 2026
04:30 AM EDT, 03/20/2026 (MT Newswires) -- Margaret A Horn, Chief Operating Officer, on March 17, 2026, sold 4,583 shares in Revolution Medicines ( RVMD ) for $455,919. Following the Form 4 filing with the SEC, Horn has control over a total of 157,570 common shares of the company, with 157,570 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1628171/000161071726000129/xslF345X05/form4.xml ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved